BioMarin Rises 5% After Global Patent Agreement with Ascendis

BioMarin Pharmaceutical shares gained 5% after resolving a global patent dispute with Ascendis Pharma. The agreement ends the intellectual property conflict between the two companies. According to the companies' statement, the global patent agreement will apply worldwide and prevent potential future legal disputes. The financial details of the agreement were not disclosed. The rise in BioMarin shares indicates that investors welcomed the elimination of uncertainty. Patent disputes can be a significant pressure factor on stock prices in the biotechnology sector. Under the terms of the agreement, both companies will respect each other's patent rights and have agreed on certain licensing arrangements. This development may reduce the risk perception regarding BioMarin's product portfolio. Not investment advice.